Walleye Capital
ENTA icon

Walleye Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Walleye Capital’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27,318
Closed -$151K – 4631
2025
Q1 		$151K Buy
27,318
+10,639
+64% +$65.7K ﹤0.01% 3436
2024
Q4 		$95.9K Sell
16,679
-27,220
-62% -$261K ﹤0.01% 4159
2024
Q3 		$455K Buy
43,899
+21,550
+96% +$282K ﹤0.01% 3383
2024
Q2 		$290K Buy
+22,349
New +$302K ﹤0.01% 4006
2024
Q1 		– Sell
-46,489
Closed -$437K – 5524
2023
Q4 		$437K Sell
46,489
-72,875
-61% -$679K ﹤0.01% 3054
2023
Q3 		$1.33M Buy
119,364
+92,410
+343% +$1.49M ﹤0.01% 2038
2023
Q2 		$577K Buy
+26,954
New +$795K ﹤0.01% 2325
2022
Q2 		– Sell
-63,046
Closed -$4.49M – 2466
2022
Q1 		$4.49M Buy
63,046
+33,846
+116% +$2.2M 0.12% 181
2021
Q4 		$2.18M Buy
+29,200
New +$2.29M 0.07% 310
2020
Q2 		– Sell
-5,402
Closed -$278K – 709
2020
Q1 		$278K Buy
+5,402
New +$288K 0.06% 360

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's ENTA Position: Q2 2025 in Review

Walleye Capital sold out of Enanta Pharmaceuticals (ENTA) in Q2 2025, closing a stake of 27,318 shares — an estimated $151K sold.

Walleye Capital first reported a position in ENTA in Q1 2020 and held it in 10 quarters. The position peaked at $4.49M in Q1 2022. 107 funds tracked by Wall St. Rank hold ENTA as of Q2 2025.

  • Walleye Capital reported no remaining Enanta Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 27,318 Enanta Pharmaceuticals shares in Q2 2025, an estimated $151K.
  • Walleye Capital first reported a position in Enanta Pharmaceuticals in Q1 2020 and held it in 10 quarters.
  • Walleye Capital's Enanta Pharmaceuticals position peaked at $4.49M in Q1 2022.
  • 107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.